What to know
Helix, Inc. established a large-scale registry of COVID-19 breakthrough and reinfection cases and performed both virus and host genetic sequencing.
Findings on SARS-CoV-2 surveillance and investigations
Awarded in 2022, this study aimed to characterize viral and host genetic factors associated with efficacy of vaccines against infection and severe disease, as well as factors associated with waning immunity. Contributions from this study could be used to predict breakthrough infections and adverse outcomes, enabling a more precise tailoring of the time intervals between vaccine doses and boosters.
Helix, Inc. explored viral and host genetic factors that could explain symptomatic and severe SARS-CoV-2 infections in fully vaccinated individuals. The study included analyses on breakthrough infections from three large health networks and a public United States university.